drugset
Drugs / MK-8189
last change Aug 2024 re-read 2 minutes ago

MK-8189

also known as Elpipodect

Small molecule

Developed for
schizophrenia · Alzheimer disease · bipolar I disorder
Investigated by
Merck Sharp & Dohme LLC

Trials 12 · a red edge is where a trial was stopped

today NCT06273774 · Ph 1 NCT05953740 · Ph 1 NCT05893862 · Ph 1 NCT05406440 · Ph 1 NCT05227118 · Ph 1 NCT06626464 · Ph 1 NCT04676425 · Ph 1 NCT04624243 · Ph 2 NCT04506905 · Ph 1 NCT03565068 · Ph 1 NCT03055338 · Ph 2 NCT02181803 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials
Phase 1 NCT06273774 Apr → Aug 2024 bipolar I disorder Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT05953740 Sep 2023 → Feb 2024 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT05893862 Jun 2023 → Feb 2024 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT05406440 Jul 2022 → Feb 2023 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT05227118 Jul 2022 → Jan 2023 Alzheimer disease Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06626464 May → Jul 2022 — Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT04676425 Mar 2021 → Jan 2022 — Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT04506905 Aug 2020 → Mar 2022 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT03565068 Jun 2018 → Apr 2020 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT02181803 Aug 2014 → Apr 2015 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 22 trials
Phase 2 NCT04624243 Dec 2020 → Jun 2024 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT03055338 Mar 2017 → Jan 2018 schizophrenia Merck Sharp & Dohme LLC Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as MK-8189 “A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)” NCT04676425 ↗
2

NCT03565068 ↗

NCT05953740 ↗
Known as Elpipodect ClinicalTrials.gov intervention name — accepted as the source's own label NCT04506905 ↗
9

NCT02181803 ↗

NCT05227118 ↗

NCT06273774 ↗

NCT06626464 ↗

NCT04676425 ↗

NCT05406440 ↗

NCT03055338 ↗

NCT04624243 ↗

NCT05893862 ↗
Modality Small molecule — CHEMBL5314924 ↗
Route Oral “Oral CR tablets (4 mg) administered QD” NCT03055338 ↗